Progress through mitosis requires that the right protein be degraded at the right time. One ubiquitin ligase, the anaphase-promoting complex or cyclosome (APC/C) targets most of the crucial mitotic regulators by changing its substrate specificity throughout mitosis. The spindle assembly checkpoint (SAC) acts on the APC/C co-activator, Cdc20 (cell division cycle 20), to block the degradation of metaphase substrates (for example, cyclin B1 and securin), but not others (for example, cyclin A). How this is achieved is unclear. Here we show that Cdc20 binds to different sites on the APC/C depending on the SAC. Cdc20 requires APC3 and APC8 to bind and activate the APC/C when the SAC is satisfied, but requires only APC8 to bind the APC/C when the SAC is active. Moreover, APC10 is crucial for the destruction of cyclin B1 and securin, but not cyclin A. We conclude that the SAC causes Cdc20 to bind to different sites on the APC/C and this alters APC/C substrate specificity.
chicken DT40 cells can divide correctly [20] [21] [22] [23] . Depleting Cdh1 in human cells stabilizes the Aurora kinases, but other late mitotic substrates, such as Plk1, are still degraded 24 . Thus, there must be other means by which the APC/C alters its substrate specificity.
One model for how APC/C complexes can discriminate between substrates is that ubiquitylation is more processive on some substrates than others 25 . Processively ubiquitylated substrates should be degraded first because they can be polyubiquitylated in one round, making them less likely to be deubiquitylated by antagonistic deubiquitylases than 'distributive' substrates that require several rounds of binding and release 25 . However, this model uses cyclin A as a model distributive substrate and securin as a processive substrate, but in mitosis, cyclin A is degraded before securin 1 . The E2 enzyme, UbcH10, has also been suggested to regulate APC/C substrate selection 26, 27 , but both mitosis and cyclin degradation are unperturbed when UbcH10 levels are depleted by more than 90% (ref. 28) .
The SAC clearly regulates the selection of some substrates over others. Some substrates are degraded when the SAC is active (prometaphase), such as cyclin A and Nek2A, but others are degraded only when the SAC is satisfied (metaphase), such as cyclin B1 and securin [29] [30] [31] [32] . Henceforth, we refer to cyclin A and Nek2A destruction as SAC-insensitive, and cyclin B1 and securin destruction as SAC-sensitive.
Recently we showed that cyclin A is degraded when the SAC is active because it binds directly to Cdc20, and is recruited by its Cks1 subunit to the APC/C (refs 33,34) . Nek2A also binds directly to the APC/C through its carboxyl terminus 35 , which has the dipeptide methionine-arginine (MR) that resembles the isoleucine-arginine (IR) The fluorescence of individual cells was measured, the value at the time of nuclear envelope breakdown (NEBD) was set to 1 and the data were plotted as thin grey lines. The mean ± s.d. for all cells is plotted as a thick black line. n, number of cells analysed from three independent experiments. (c) Depletion of human APC11. Cells were treated with siRNA oligonucleotides against GAPDH or APC11 for 72 h before assaying the indicated amounts of extract by quantitative immunoblotting. The extent of depletion was calculated from a standard curve using diluted control extract and normalization to the level of tubulin. Results are representative of at least two experiments per siRNA treatment. (d,e) APC11 is required to degrade both SAC-sensitive and SAC-insensitive substrates. Cells were treated with siRNA oligonucleotides against APC11, injected with a plasmid encoding cyclin A-Venus (d) or cyclin B1-Venus (e) and analysed as in a. For cells treated with APC11 siRNA, data for individual cells are plotted as thin grey lines, and the mean ± s.d. is plotted as a thick black line. The control values are shown as a thick grey line and for d,e were as measured in a,b, respectively. n, number of cells analysed from three independent experiments. (f) The SAC stabilizes cyclin A-Venus in cells depleted of APC11. Cells were treated with siRNA oligonucleotides against GAPDH (thick grey line; mean ± s.d.) or APC11 (thick black line, mean ± s.d.; data for individual cells, thin grey lines), injected with a plasmid expressing cyclin A-Venus, treated with 100 ng ml −1 nocodazole and analysed as in a. n, number of cells analysed from two independent experiments. (g) Cyclin A is preferred over securin as a substrate when APC/C activity is limiting. Cells were treated with siRNA oligonucleotides against APC11, injected with a plasmid expressing cyclin A-Venus (black) and securin-Cerulean (grey) and analysed as in a. Representative of 11 cells in two independent experiments. Uncropped images of blots are shown in Supplementary Fig. S10 . . Cells were treated with siRNA oligonucleotides against GAPDH or APC3 for 72 h before analysing. Protein levels were analysed as in Fig. 1c . (b,c) APC3 is required to degrade both SAC-insensitive and SAC-sensitive substrates. Cells were treated with siRNA oligonucleotides against APC3, injected with a plasmid encoding cyclin A-Venus (b) or cyclin B1-Venus (c) and analysed as in Fig. 1a . For cells treated with APC3 siRNA, data for individual cells are plotted as thin grey lines, and the mean ± s.d. is plotted as a thick black line. The control values are shown as a thick grey line and for b,c were measured in Fig. 1a ,b, respectively. n, number of cells analysed from three independent experiments. (d) APC/C composition in the depletion of APC3 or APC10. Top: HeLa cells were treated with siRNA against GAPDH, APC3 or APC10 for 72 h before collecting prometaphase cells in the presence of 100 ng ml −1 nocodazole by mitotic shake off. Total cell extracts were immunoblotted with antibodies against APC3, APC7 and APC10. Heat-shock protein 70 (Hsp70) was used as a loading control. Bottom: the APC/C was immunoprecipitated using anti-APC4 antibodies and the immunoprecipitates blotted with antibodies against phospho-APC1 (Ser 355), APC2, APC3, APC4, APC6, APC7, APC8, APC10 and APC11. (e) Analysis of APC/C composition in APC3-depleted cells by size-exclusion chromatography. Extracts of control (top) or APC3-depleted (bottom) cells were separated on a Superose 6 column and fractions were blotted with antibodies against APC3, APC4 and APC6. The total cell extract is also shown (top right). Loading control refers to a cross-reacting protein recognized by the anti-APC3 antibody. The peak of APC/C migration is indicated by the black bar. Uncropped images of blots are shown in Supplementary Fig. S10 . The maximal slope of the cyclin degradation was calculated by using the curve-fit function in Prism software and the standard deviation calculated. The P value compared to control cells was calculated by a Student's t -test.
dipeptide at the C terminus of Cdc20, Cdh1 and APC10 (ref. 36) , and is required for Cdh1 to interact with the APC3 subunit 3, 36 . Whether all APC/C substrates bind to the same binding site, (and it is the timing of their recruitment that regulates when they are ubiquitylated), or whether different substrates are bound to different binding sites on the APC/C, is unknown.
Here we have begun to analyse the contribution that APC/C subunits make to the targeting of specific mitotic substrates. We have used short interfering RNA (siRNA) to deplete particular subunits and assayed the binding of substrates and Cdc20 to the APC/C, and investigated the subsequent effect on the degradation of specific substrates using a live-cell assay. We present evidence that the APC/C does indeed recognize its SAC-insensitive substrate cyclin A in a different manner from its SAC-sensitive substrates, cyclin B1 and securin, and this is determined by the manner in which Cdc20 binds to the APC/C. We show that when the SAC is active, Cdc20 primarily requires APC8 to bind to the APC/C, whereas it requires APC3 and APC8 when the SAC is satisfied. The interaction with APC8 is important for APC/C activity in the presence and absence of the SAC. Furthermore, once the SAC is satisfied, Cdc20 works together with APC10 to provide a binding site for SAC-sensitive substrates. Thus, our results give insights into how the SAC regulates Cdc20 and the APC/C, and consequently how this alters APC/C substrate specificity.
RESULTS
To determine how the APC/C and the SAC work together to target different substrates for degradation when the SAC is active in prometaphase, compared with when the SAC is satisfied in metaphase, we depleted individual APC/C subunits by siRNA in human cells and assayed the effect on fluorescent protein (FP)-tagged substrates using a live-cell assay 29 . This allowed us to determine whether depletion affected the timing and the rate of destruction of specific substrates. We chose cyclin A as a model SAC-insensitive substrate and cyclin B1 and securin as SAC-sensitive substrates. Cyclin A-FP is degraded rapidly in prometaphase as soon as the nuclear envelope breaks down 30, 31 (NEBD), whereas cyclin B1-FP and securin-FP begin to be degraded only once all of the chromosomes have attached to the spindle and satisfied the SAC (Fig. 1a,b and Supplementary Fig. S1 ; refs 29,30,37) .
Cyclin A is preferred to securin in cells with limiting levels of APC/C-depleted activity
We first assayed the effect of reducing overall APC/C activity in cells by depleting APC11, the catalytic subunit that recruits the E2 protein 4, 38 . Depleting APC11 by >85% ( Fig. 1c ) delayed cells in mitosis (Supplementary Fig. S2b ) and prevented or markedly impaired the degradation of all the substrates we analysed: cyclin A ( Fig. 1d ), cyclin B1 ( Fig. 1e ; quantified in Table 1 ) and securin ( Supplementary Fig. S1b ). The effect of the siRNA was specific, because we could rescue the phenotype by expressing a siRNA-insensitive version of the subunit, as we could for all of the other APC subunit depletions in our study ( Supplementary Fig. S2 ).
In APC11-depleted cells, cyclin A began to be degraded when cells reached metaphase, indicating that degradation might now be more sensitive to the SAC ( Supplementary Fig. S3 ). We provided direct support for this interpretation by adding nocodazole to maintain the SAC, which stabilized cyclin A ( Fig. 1f ). As cyclin A degradation now began at the same time as the SAC-sensitive substrates, we could directly test the 'processivity model' for substrate selection. Therefore, we co-expressed cyclin A-Venus and securin-cyan fluorescent protein (CFP) in APC11-depleted cells and, in contradiction to the model, cyclin A (a 'distributive' substrate) was preferentially degraded over securin (a 'processive' substrate; Fig. 1g ).
APC3 is required to degrade both SAC-sensitive and SAC-insensitive substrates
To address the question of whether APC/C subunits contribute to the change in APC/C substrate selection, we depleted the APC3 subunit that binds to the IR tail of APC/C co-activators 3, 36 . Mutations in the APC3 gene in yeast 39 and in Drosophila 40 showed that it was required to degrade mitotic cyclins and, in agreement with this, depleting APC3 by siRNA to ∼90% ( Fig. 2a ) severely delayed and inhibited the degradation of human cyclin A (Fig. 2b ), cyclin B1 ( Fig. 2c ; quantified in Table 1 ) and securin ( Supplementary Fig. S1c ). 
Relative protein level bound to APC/C Relative protein level bound to APC/C Figure 3 APC3 is required to bind Cdc20 only when the SAC is satisfied. (a-d) HeLa cells were treated with siRNA against GAPDH (control) or APC3 and synchronized in prometaphase by treating with 100 ng ml −1 nocodazole plus 10 µM MG132 to stabilize cyclin A (a,b), or synchronized in prometaphase with 100 ng ml −1 nocodazole, released into medium containing 10 µM MG132 and incubated for a further 3 h to obtain metaphase cells (c,d). The APC/C complex was immunoprecipitated with anti-APC4 antibodies and samples blotted for APC3, APC4, Cdc20, BubR1 and cyclin A (a) or cyclin B1 (c). (b,d) Bar diagrams show the remaining amount of APC3 and the amount of Cdc20 and cyclin A or B1 bound to the prometaphase APC/C (b) or the metaphase APC/C (d), in APC3-depleted cells quantified using a LI-COR Odyssey scanner and normalized to the level of APC4. Levels of the proteins bound to control APC/C were set to 1. Error bars, mean ± s.d. of three experiments. (e) APC3 is required for free Cdc20 to bind to the APC/C. Cells were treated with siRNA oligonucleotides against GAPDH or APC3 and synchronized as in a. Purified recombinant 6 × His-tagged Cdc20 was added to the cell extracts and the APC/C was immunoprecipitated with an anti-APC4 antibody. Samples were blotted for APC3, APC4 and Cdc20. Recombinant Cdc20 has a higher molecular mass than endogenous Cdc20. Uncropped images of blots are shown in Supplementary Fig. S10 .
APC3 is required for the APC/C to bind Cdc20 only when the SAC is satisfied
To understand the requirement for APC3, we assayed APC/C composition and the binding of co-activator and substrates in APC3-depleted cells. Depleting APC3 destabilized APC10 and APC7 ( Fig. 2d ) and reduced the amount of APC10 and APC7 bound to the complex (Fig. 2d ), but the composition of the rest of the APC/C was largely unaltered, as assayed by co-immunoprecipitation and size-exclusion chromatography ( Fig. 2d,e ). These minimal effects on the overall APC/C structure agree with the analysis of deleting the APC3 gene (Cdc27 ) in budding yeast 3 .
Depleting APC3 markedly reduced the binding of both cyclin A ( Fig. 3a,b ) and cyclin B1 ( Fig. 3c,d ), most likely because cyclin A is recruited through its Cks1 subunit to phospho-APC3, whereas cyclin B1 requires Cdc20 to bind to the APC/C (see below). When we assayed the binding of Cdc20, however, we noted a striking difference between the APC/C immunopurified from cells with an active SAC (prometaphase, Fig. 3a ) and those in which the SAC was satisfied (metaphase, Fig. 3c ). Depleting APC3 had no apparent effect on the amount of Cdc20 bound to the APC/C when the SAC was active, but significantly reduced the amount bound when the SAC was satisfied (compare Fig. 3a and c; quantified in Fig. 3b and d ). That these effects were specific to the depletion of APC3 was confirmed by rescuing the depletion with siRNAresistant APC3, which also restored APC10 binding ( Supplementary Fig.  S4 ). We reasoned that this difference might be because in prometaphase Cdc20 bound to the APC/C as part of a SAC-complex but as a free protein in metaphase, and consistent with this, exogenous Cdc20 could not bind to the APC/C in prometaphase in the absence of APC3 (Fig. 3e ). Thus, we conclude that Cdc20 binds to a different site on the APC/C depending on whether the SAC is active or not.
APC10 and Cdc20 are both required to recruit SAC-sensitive substrates
Our observation that depleting APC3 also caused a reduction in APC7 and APC10 levels meant that these proteins might also have important roles in recognizing substrates. To test this, we depleted APC7 ( Supplementary Fig. S5 ) or APC10 by siRNA ( Fig. 4a ) and assayed the destruction of cyclin A and cyclin B1 (Fig. 4b,c ; quantified in Table 1 ). Depleting APC7 had no visible effect on cyclin B1 degradation, and caused only a minor delay in the destruction of cyclin A, which was still degraded when cells were treated with nocodazole ( Supplementary  Fig. S5 ). Although depleting APC10 had no effect on the degradation of (b,c) APC10 is required for cyclin B1, but not for cyclin A, degradation. Cells were treated with siRNA oligonucleotides against APC10, injected with a plasmid encoding cyclin A-Venus (b) or cyclin B1-Venus (c) and analysed by time-lapse DIC and fluorescence microscopy as in Fig. 1a . For cells treated with APC10 siRNA, data for individual cells are plotted as thin grey lines, and the mean ± s.d. is plotted as a thick black line. The control values are shown as a thick grey line and for b,c were measured in Fig. 1a ,b, respectively. n, number of cells analysed from two independent experiments. (d,e) APC10 mediates cyclin B1 and Cdc20, but not cyclin A, binding to APC/C. HeLa cells were treated with siRNA against GAPDH (control) or APC10 and synchronized in metaphase as in Fig. 3c . The APC/C complex was immunoprecipitated with anti-APC4 antibodies and samples were blotted for APC3, APC4, APC10, Cdc20, cyclin A and cyclin B1 (d). (e) Bar diagrams show the remaining amount of APC10 and the amount of cyclin B1 and Cdc20 bound to the metaphase APC/C in APC10-depleted cells quantified using a LI-COR Odyssey scanner and normalized to the level of APC4. Levels of the proteins bound to control APC/C were set to 1. The mean ± s.d. of three experiments is shown. Uncropped images of blots are shown in Supplementary Fig. S10. cyclin A, which began at the correct time and proceeded at its normal rate ( Fig. 4b) , it delayed the timing and slowed the rate of cyclin B1 (and securin) destruction ( Fig. 4c and Supplementary Fig. S1d ). Consistent with this, depleting APC10 perturbed the binding of cyclin B1, but not cyclin A, to the APC/C (Fig. 4d ). Cyclin B1 primarily bound to the APC/C as a substrate because mutating the destruction box of cyclin B1 severely reduced its binding ( Supplementary Fig. S6 ).
Depleting APC10 also reduced the amount of Cdc20 bound to the APC/C in metaphase ( Fig. 4d,e ), but not prometaphase (data not shown). In yeast, APC10 is important for the APC/C to recognize substrates with a destruction box 15, 41 by forming a bipartite receptor with Cdc20 (ref. 42 ); therefore, we tested whether depleting Cdc20 had a similar effect on substrate binding. In accord with this idea, depleting Cdc20 markedly reduced the binding of cyclin B1 to the APC/C in metaphase ( Supplementary Fig. S7a ). In contrast, depleting Cdc20 increased the amount of cyclin A bound to the APC/C when the SAC was active ( Supplementary Fig. S7b ), indicating that Cdc20 was not required to recruit cyclin A to the APC/C. Thus, we conclude that, as in budding yeast 42, 43 , APC10 and Cdc20 stabilize each other's binding to the APC/C and are both required to bind canonical destruction box substrates to the APC/C when the SAC is satisfied. However, they are not required to recruit cyclin A to the APC/C when the SAC is active. Instead, cyclin A is recruited by its Cks subunit 33 and we infer that Cdc20 must activate the APC/C (ref. 34) , as suggested for Nek2A destruction 44 .
To bind Cdc20 and degrade cyclin A when the SAC is active the APC/C requires APC8
As Cdc20 did not require APC3 to bind to the APC/C when the SAC was active, we sought to identify its prometaphase binding site. By siRNA phenotypes, we identified APC6 and APC8 as particularly important to bind Cdc20 in prometaphase ( Supplementary Fig. S8 ). Analyses in budding yeast, however, showed that eliminating APC6 (Cdc16 ) and APC8 (Cdc23) perturbed APC/C structure 3 . To eliminate the possibility that depleting APC6 or APC8 reduced Cdc20 binding by disrupting the APC/C, we sought a point mutation to perturb Cdc20 binding. and extracts prepared as in Fig. 3e . Cell extracts were fractioned on a Superose 6 column and fractions were blotted with antibodies against APC3, APC4, Flag epitope, APC8, Cdc20 and BubR1. The peak of APC/C migration is indicated by the black bar. (Endogenous APC8; endogenous APC8). Uncropped images of blots are shown in Supplementary Fig. S10 . A point mutation in the TPR motifs of APC8 (Cdc23) that reduced binding to Cdh1 was previously identified (ref. 42 ). Therefore, we made the analogous mutation (N338A) in human APC8 ( Fig. 5a ) and expressed this in cells depleted of APC8 by siRNA. Compared with cells rescued with wild-type APC8, the APC8 N338A mutant reduced the amount of Cdc20 bound to the APC/C in prometaphase (Fig. 5b,c) , but had no effect on the composition of the APC/C (Fig. 5b) . Size-exclusion chromatography confirmed that less Cdc20 bound to the APC/C incorporating the APC8 N338A point mutant ( Fig. 5d ) and showed both that the APC/C migrated at its correct size (M r (K), 1,500) and incorporated the Flag-tagged wild-type and mutant APC8 constructs to a similar extent (Fig. 5d ). Consistent with the reduction in Cdc20 binding, the APC8 N338A mutant delayed cells in mitosis ( Supplementary  Fig. S9 ) and notably delayed the destruction of cyclin A by around 12 min ( Fig. 6a,b ; quantified in Table 1 ).
In cells rescued with the APC8 N338A mutant, we noticed that the destruction of cyclin A correlated with chromosome alignment, indicating that cyclin A might be degraded only once the SAC had been satisfied. To test this, we assayed cyclin A-FP degradation after adding nocodazole to prevent the SAC being satisfied, and found that in contrast to cells expressing wild-type APC8, cyclin A was stabilized by nocodazole ( Fig. 6c,d ; quantified in Table 1 ). We conclude that when the SAC is active, APC8 is crucial for Cdc20 to bind the APC/C, and binding to this site is important for cyclin A degradation.
The Cdc20-binding site on APC8 is required for cyclin B1 destruction in metaphase
As cyclin A could be degraded in APC8 N338A -expressing cells once the SAC was satisfied, this could mean that the APC8 site was no longer required for APC/C activity. Alternatively, as cyclin A binds directly to Cdc20 and itself binds to the APC/C through Cks1, it might be a special case. Therefore, we assayed the degradation of cyclin B1 in cells expressing the APC8 N338A mutant and found that its destruction was also inhibited ( Fig. 7a,b ; quantified in Table 1 ). Furthermore, the APC8 N338A mutation reduced both the binding of Cdc20 when the SAC was satisfied ( Fig. 7c) and APC/C activity in vitro (Fig. 7d ). Thus, we conclude that APC8 has a crucial role to activate the APC/C in the presence or absence of the SAC.
DISCUSSION
In this paper we have begun to determine the mechanism behind the ability of the APC/C to recognize different proteins at different times (Fig. 7e) , which is crucial to the proper coordination of chromosome segregation and cytokinesis. We find that the APC/C binds to Cdc20 in a different manner when the SAC is active, compared with when Figure 7 The Cdc20-binding site on APC8 is also required in metaphase. (a,b) Cyclin B1 degradation is inhibited in cells expressing APC8 N338A . siRNA against APC8 and a plasmid encoding cyclin B1-Venus were transfected into the HeLa cells with an inducible siRNA-resistant wild-type Flag-APC8 (a) or mutant Flag-APC8 N338A (b) and analysed as in Fig. 1a . Mean ± s.d. values are shown. n, number of cells analysed from three independent experiments. (c) APC8 is important for free Cdc20 to bind to the APC/C. HeLa cells expressing an inducible wild-type Flag-APC8 (WT) or mutant Flag-APC8 N338A were treated with siRNA against GAPDH (control) or APC8 as in Fig. 5b and synchronized in metaphase as in Fig. 3c . The APC/C was immunoprecipitated using anti-APC4 antibodies and the immunoprecipitates blotted with antibodies against APC4, APC8 and Cdc20. The asterisks indicate endogenous APC8.
(d) The APC8 N338A mutation reduces APC/C activity in vitro. The APC/C incorporating wild-type Flag-APC8 (WT) or Flag-APC8 N338A was prepared as in Fig. 5b and its activity assayed using securin as a substrate in an in vitro ubiquitylation reaction as previously described 49 . (e) Model for APC/C regulation during early mitosis. In prometaphase (left), the APC/C recognizes substrates such as cyclin A through the APC3 subunit, but interacts through APC8 with Cdc20, as co-activator or as part of the SAC complex. The SAC proteins associated with Cdc20 could prevent Cdc20 accessing its APC3 binding site. In metaphase (right), the APC/C recognizes substrates such as cyclin B1 through APC10 and Cdc20 forming a bipartite receptor, and Cdc20 requires both APC3 and APC8 to interact with and activate the APC/C. Uncropped images of blots are shown in Supplementary Fig. S10 .
the SAC is satisfied. Our evidence is consistent with a site on APC8 that is particularly important to bind Cdc20 when the SAC is active, whereas APC3 also becomes important when the SAC is satisfied. Our conclusion is consistent with the most recent APC/C structures obtained by cryo-electron microscopy tomography where Cdc20 seems to bind to a different part of the APC/C depending on whether the APC/C was purified from prometaphase or metaphase cells 45 . Furthermore, that APC3 and APC8 might both interact with Cdc20 is consistent with recent single-particle electron microscopy analysis of the budding yeast APC/C coupled to a crystal structure of the APC3-Cdc27 amino-terminal dimerization domain, which indicates that APC8-Cdc23 and APC3-Cdc27 are homodimers with similar overall three-dimensional structures 46 (Schreiber et al., in preparation).
In agreement with previous studies in budding yeast, we find that APC10 and Cdc20 are both required to bind substrates to the APC/C once the SAC is satisfied, and thus are likely to act as a bipartite receptor for substrates with canonical destruction boxes. Just as in budding yeast 15 , we were able to detect only the ternary complex of APC/C-Cdc20-cyclin B1, and we find that APC10 and Cdc20 stabilize each other on the APC/C. At this time in mitosis, Cdc20 is likely to bind to APC3, probably through its IR tail. In contrast, neither APC10 nor Cdc20 is required to form the binding site for cyclin A when the SAC is active. Instead APC3 is required, most likely through binding the Cks protein that itself binds to the cyclin A-Cdk complex 33 .
In cells with limiting APC/C activity, cyclin A is preferred as an APC/C substrate over cyclin B1 and securin. This result is not consistent with the 'processivity' model for how the APC/C chooses its substrates 25 . This model, however, was based on experiments using an in vitro ubiquitylation assay 25 where it was not clear whether cyclin A was bound to its partner Cdk and Cks proteins that are required to recruit cyclin A to the APC/C (refs 33,34) .
We find that APC8, but not APC3, is important to bind Cdc20 when the SAC is active, and the potential interaction site is conserved in yeast 42 . Mutating this site reduces Cdc20 binding to the APC/C when the SAC is active, and prevents cyclin A destruction even though cyclin A is still bound to the APC/C. Once the SAC is satisfied, cyclin A is degraded, indicating that the Cdc20 recruited by cyclin A can activate the APC/C. However, the APC/C binds less Cdc20 and is unable to degrade cyclin B1 in vivo, and has greatly reduced activity in vitro. Thus, APC8 provides an important site for APC/C activity in prometaphase and metaphase. Consistent with this, the Cdc23 N405A mutation interfered with the ubiquitylation of securin and destruction of Clb2, as well as the binding of Cdh1 (ref. 42 ). Thus, the interaction between APC8 and co-activator is important for APC/C activity throughout mitosis.
How Cdc20 activates the APC/C is unclear, but it might change APC/C conformation as proposed for Cdh1 (ref. 47) . Recent evidence indicates that this activation ability lies in the N terminus of Cdc20 (ref. 44) . Two motifs of Cdc20 are required to bind and activate the APC/C: the C-box in the N terminus, and the C-terminal IR-tail 48, 49 . A C-terminal peptide of Cdc20 interacts with recombinant APC3 and APC7 (ref. 36 ) and genetically the IR motif of Cdh1 interacts with APC3-Cdc27 (refs 3,42) , whereas the C-box of Cdh1 seems to bind APC2 (ref. 3) . The site that interacts with APC8 is not yet known, but it does not seem to be either the IR domain or the C-box 42 .
That APC10 is required to bind only SAC-sensitive substrates has implications for models for how the SAC acts on the APC/C, raising the possibility that the SAC might act on APC10. Some phosphorylation sites on the APC/C specifically respond to different microtubule poisons and thus potentially depend on different SAC kinases 50 . Moreover, the ability to maintain an arrest in mitosis differs in response to different microtubule poisons 51 . If SAC kinases directly regulate APC/C activity by phosphorylation, then APC10 is a potential target.
The well-established target of the SAC is Cdc20, which is incorporated into a BubR1-Bub3 complex by the SAC (refs 49,52,53 ) and we think this blocks its ability to provide a binding site (with APC10) for cyclin B1, because we never detected an interaction between cyclin B1 and the APC/C or Cdc20 in prometaphase extracts (data not shown). In contrast, it was found that cyclin B1 associated with the prometaphase APC/C (ref. 54) . At present, we cannot explain this discrepancy.
We find that the Cdc20-BubR1-Bub3 complex binds to a site requiring APC8 and not APC3. There is evidence that Mad3 (BubR1) acts as a pseudosubstrate 55 ; therefore, BubR1-Bub3 might physically prevent Cdc20 from accessing APC3 to form the metaphase substrate binding site (with APC10). Alternatively, the BubR1-Bub3 complex might prevent Cdc20 from interacting with APC10, thereby blocking Cdc20 activity against metaphase substrates. Definitive answers to these questions will require more structural studies of the APC/C. bovine serum. For synchronization at the beginning of S phase, HeLa cells were treated with 2.5 mM thymidine or 2.5 mM thymidine followed by 2.5 µg ml −1 aphidicolin as previously described 56 . For prometaphase, cells were released from a double thymidine block and 6 h later treated with nocodazole at a final concentration of 0.1 ng µl −1 for 12 h. For metaphase, cells were released from the nocodazole block into medium containing 10 µM MG132 for 3 h.
METHODS

Methods
RNA interference. The following ON-TARGETplus (Dharmacon) oligonucleotides were used: APC3-1 (5 -GGAAAUAGCCGAGAGGUAAUU-3 ) and APC3-2 (5 -CAAAAGAGCCUUAGUUUAAUU-3 ), APC11-1 (5 -UCUGCAGGAUGGC− AUUUAAUU-3 ), APC11-2 (5 -AAGAUUAAGUGCUGGAACGUU-3 ), APC10-1 (5 -GAGCUCCAUUGGUAAAUUUUU-3 ), APC10-2 (5 -GAAAUUGGGUCAC − AAGCUGUU-3 ), APC6-1 (5 -CUAUGGACCUGCAUGGAUAUU-3 ), APC6-2 (5 -CGAGGUAACAGUUGACAAAUU-3 ), APC8-1 (5 -GAAAUUAAAUCCUCGGUA− UUU-3 ), APC8-2 (5 -GCAGUUGCCUAUCACAAUAUU-3 ) and GAPDH (D-001830-01). Cells were transfected with 100 nM of a mixture of two oligonucleotides using Oligofectamine (Invitrogen). Cells were transfected twice: first for 24 h after which siRNA oligonucleotides were transfected again for a further 48 h before collecting cells for immunoprecipitation or analysing by microscopy.
Microscopy. Cells were incubated on the microscope using the Delta T system (Bioptechs) and imaged by time-lapse fluorescence and differential interference contrast (DIC) microscopy on a Leica DMIRBE or DMIR2 microscope equipped with a ×40 1.2 NA oil immersion lens. Cerulean-CFP and Venus-yellow fluorescent protein (YFP) were visualized using a JP5 filter set (Chroma) with excitation and emission filters in filter wheels (Lambda 10-3, Sutter Instrument Co) and a Cascade 512B or QuantEM CCD (charge-coupled device) camera (Photometrics). Multiple cell positions were captured using a Corvus (Marzhauser) or H117 (Prior) stage. Shutters (Smart shutter, Sutter Instrument Co), filter wheels, stages, microscopes and cameras were all controlled by SlideBook software (Intelligent Imaging Innovations). Images were captured at 3 min intervals and analysed using SlideBook. Images were exported to ImageJ to assemble into movies.
Immunoprecipitation. Protein complexes were immunoprecipitated with antibodies covalently coupled to Dynabeads (Invitrogen) using HEPES buffer (100 mM KaCl, 40 mM HEPES at pH 7.8, 10 mM EDTA, 10% glycerol, 0.1% NP-40, 1 mM dithiothreitol, Roche complete inhibitor cocktail tablet, 0,2 µM microcystin and 1 mM phenylmethyl sulphonyl fluoride) for incubation and washing. Cells for immunoprecipitation were lysed with HEPES buffer for 10 min on ice and clarified by a 20,000g spin for 10 min.
Gel filtration column chromatography. Cells were resuspended in buffer A (140 mM NaCl, 30 mM HEPES at pH 7.8, 6 mM MgCl2, 5% glycerol, 1 mM dithiothreitol, Roche complete inhibitor cocktail tablet, 0,2 µM microcystin and 1 mM phenylmethyl sulphonyl fluoride) at a 1:1 ratio of buffer to cells, and opened by nitrogen cavitation (1,000 psi, 30 min, Parr Instrument). Lysed cells were centrifuged at 20,000 g for 10 min and 259,000g for 10 min before loading on Superose 6 PC 3.2-30 (GE Healthcare). The column was run at a flow of 25 µl min −1 in buffer B (140 mM NaCl, 30 mM HEPES 7.8, 5% glycerol and 1 mM dithiothreitol) and 50 µl fractions were collected.
Antibodies. The following antibodies were used at the indicated dilutions. Cdc20 (A301-180A, Bethyl Laboratories) 1:200; BubR1 (A300-386A, Bethyl Laboratories), 1:500; cyclin B1 (mAb GNS-1, BD Pharmingen) 1:1,000; cyclin A (mAb AT10.3, CRUK) 1:1,000; APC3 (610455, BD Transduction Laboratories) 1:500; APC4 (monoclonal antibody raised against a C-terminal peptide) 1:500; APC11 (monoclonal antibody raised against a C-terminal peptide) 1:500; APC7 (Abcam 4171) 1:500; APC8 (Biolegend) 1:500; APC6 (Santa Cruz Biotechnology) and APC10 (raised against full length protein) 1:500; Hsp70 (Sigma) 1:5,000.
Secondary antibodies used for LI-COR: Alexa Flour 680 rabbit anti-goat (A21088), Alexa Fluor 680 goat anti-mouse (A21057) and Alexa Fluor 680 goat anti-rabbit (A21076), all used at 1:5,000.
Quantitative immunoblotting. After blotting with primary antibodies, blots were incubated with fluorescently labelled secondary antibodies and the fluorescence measured using a LI-COR Odyssey CCD scanner according to the manufacturer's instructions (LI-COR Biosciences). HeLa cells expressing FLAG-Venus-APC3 or empty FLAG-Venus from an inducible promoter were treated with siRNA against GAPDH (CTR) or APC3 and synchronised in prometaphase by treating with 100 ng/ml nocodazole plus 10 µM MG132 to stabilise Cyclin A (a) or were synchronised in prometaphase with 100 ng/ml nocodazole, released into medium containing 10 µM MG132 and incubated for a further 3 hrs to obtain metaphase cells (b). The APC/C complex was immunoprecipitated with anti-APC4 antibodies and samples blotted for APC3, APC4, APC10, Cdc20, BubR1 and Cyclin A (a) or Cyclin B1 (b). Protein levels were measured for Cyclins A and B1 and Cdc20 using a Li-COR scanner and the values normalised to control cells. The APC/C was immunoprecipitated using anti-APC4 antibodies and the immunoprecipitates blotted with antibodies against APC4, APC7, Cdc20 and Cyclin A. Protein levels were analysed by quantitative immunoblotting. 
